Blueblood Ventures reports net profit of ₹3.26 lakh in FY26

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights

Blueblood Ventures Limited reported a net profit of ₹3.26 lakh for the financial year ended March 31, 2026, compared to ₹0.59 lakh in the previous year. Total revenue increased to ₹110.64 lakh from ₹80.08 lakh in FY25. The Board of Directors approved the standalone annual audited financial results on May 27, 2026. Statutory auditors M/s KRA & Associates issued an unmodified opinion but highlighted an emphasis of matter regarding wrongly transferred Zero Optional Convertible Debentures and pending confirmations for long-term loans.

powered bylight_fuzz_icon
41422184

*this image is generated using AI for illustrative purposes only.

Blueblood Ventures Limited reported a net profit of ₹3.26 lakh for the financial year ended March 31, 2026, a significant increase from ₹0.59 lakh in the previous year. Total revenue for the period rose to ₹110.64 lakh, compared to ₹80.08 lakh in FY25. The company's Board of Directors approved the standalone annual audited financial results at a meeting held on May 27, 2026.

The statutory auditors, M/s KRA & Associates, issued an unmodified opinion on the financial results. However, the auditors highlighted an emphasis of matter regarding Zero Optional Convertible Debentures (ZOCDs) valued at ₹1155.00 lakhs. The report noted that 247 ZOCDs were wrongly transferred to a party, and management is in the process of recovering them into the DEMAT account. Additionally, pending confirmations for old debit balances in long-term loans and advances amounting to ₹6346.28 lakhs were considered good based on management's optimism for recovery.

Revenue from operations for FY26 stood at ₹79.18 lakh, up from ₹50.02 lakh in the prior year. Other income contributed ₹31.46 lakh to the total revenue. Total expenses for the year increased to ₹106.36 lakh from ₹79.27 lakh in FY25. The company reported a profit before tax of ₹4.27 lakh for FY26, compared to ₹0.81 lakh in the previous year.

The earnings per share (EPS) for the year improved to ₹0.11 from ₹0.02 in the previous year. The paid-up equity share capital remained constant at ₹300.11 lakh. The company also noted that it had applied for the Sabka Vishwas (Legacy Dispute Resolution) Scheme, 2019, to settle a service tax matter of ₹27.04 lakhs related to FY18.

Financial Performance Summary

Particulars FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Total Revenue 110.64 80.08
Total Expenses 106.36 79.27
Profit Before Tax 4.27 0.81
Net Profit 3.26 0.59
Earnings Per Share (EPS) 0.11 0.02

Balance Sheet Highlights

As of March 31, 2026, the company's total assets stood at ₹9,918.70 lakh, a decrease from ₹10,024.14 lakh in the previous year. Non-current investments were recorded at ₹1,229.73 lakh, while long-term loans and advances amounted to ₹6,346.28 lakh. Trade receivables decreased to ₹1,398.69 lakh from ₹2,127.41 lakh in FY25. The company's cash and cash equivalents improved marginally to ₹10.58 lakh from ₹9.48 lakh.

What is the expected timeline for the recovery of the wrongly transferred 247 ZOCDs, and what impact will a delay have on the company's liquidity?

Does the management's optimism regarding the recovery of ₹6346.28 lakhs in pending long-term loans rely on specific legal actions or debtor settlements?

How will the resolution of the ₹27.04 lakh service tax dispute under the Sabka Vishwas scheme affect the company's cash flow in the upcoming fiscal year?

like20
dislike

Blueblood Ventures Limited Schedules Board Meeting on May 27, 2026 to Approve FY26 Financial Results

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Blueblood Ventures Limited has intimated BSE Limited of a board meeting on May 27, 2026, at its New Delhi office, to approve audited standalone financial results for the half year and financial year ended March 31, 2026, under Regulation 29 of SEBI (LODR) Regulations, 2015. The trading window for designated persons has been closed since March 31, 2026, and is set to reopen on May 30, 2026.

powered bylight_fuzz_icon
40397594

*this image is generated using AI for illustrative purposes only.

Blueblood Ventures Limited has notified BSE Limited of an upcoming board meeting scheduled for Wednesday, May 27, 2026, pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was submitted to the Secretary of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Board Meeting Details

The board meeting will be held at the company's registered address at M-55, Third Floor, Greater Kailash-II, New Delhi – 110048. The key agenda item for the meeting is outlined below:

Parameter: Details
Meeting Date: Wednesday, May 27, 2026
Venue: M-55, Third Floor, Greater Kailash-II, New Delhi – 110048
Agenda: Approval of Audited Standalone Financial Results
Period Under Review: Half year and financial year ended March 31, 2026
Regulatory Basis: Regulation 29, SEBI (LODR) Regulations, 2015

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code for regulating, monitoring, and reporting of trading in securities by designated persons, the trading window for all designated persons, including insiders, has been closed with effect from March 31, 2026. The trading window is scheduled to reopen on May 30, 2026.

Regulatory Compliance

The intimation was signed by Suresh Bohra, Managing Director of Blueblood Ventures Limited, and submitted for the information and records of BSE Limited. The company's contact details are as follows:

How might Blueblood Ventures Limited's audited standalone financial results for FY2026 compare to its previous year's performance, and what growth trajectory could investors expect?

Will the board meeting on May 27, 2026 include any additional agenda items beyond financial results approval, such as dividend declarations or strategic announcements?

How could the trading window reopening on May 30, 2026 impact the stock's trading volume and price volatility following the release of the audited results?

like20
dislike

More News on Blueblood Ventures Limited